Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Mutual Funds

Today's Drugs Industry Featured Laggard: Endo Health Solutions Inc (ENDP)

Tickers in this article: ENDP

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model .

Endo Health Solutions ( ENDP) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.6%. By the end of trading, Endo Health Solutions fell 37 cents (-1.1%) to $34.61 on average volume. Throughout the day, 2.9 million shares of Endo Health Solutions exchanged hands as compared to its average daily volume of 2.6 million shares. The stock ranged in price between $34.43-$35.19 after having opened the day at $34.85 as compared to the previous trading day's close of $34.98. Other companies within the Drugs industry that declined today were: Synergy Pharmaceuticals ( SGYP), down 17%, iBio ( IBIO), down 9.2%, Infinity Pharmaceuticals ( INFI), down 9%, and Tekmira Pharmaceuticals Corporation ( TKMR), down 6.5%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. Endo Health Solutions has a market cap of $3.8 billion and is part of the health care sector. Shares are up 33.4% year to date as of the close of trading on Tuesday. Currently there are eight analysts that rate Endo Health Solutions a buy, three analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Endo Health Solutions as a hold. The company's strengths can be seen in multiple areas, such as its good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.

On the positive front, Star Scientific ( STSI), up 14.8%, OxiGene ( OXGN), up 14.2%, BioTime ( BTX), up 12.6%, and Agenus ( AGEN), up 9.3%, were all gainers within the drugs industry with Pfizer ( PFE) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE .